0000000000236853

AUTHOR

Raúl J. Andrade

showing 7 related works from this author

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study

2021

INTRODUCTION: Obeticholic acid (OCA) and fibrates therapy results in biochemical improvement in placebo-controlled trials in patients with primary biliary cholangitis and insufficient response to ursodeoxycholic acid. There is scarce information outside of clinical trials. Therefore, we have assessed the effectiveness and adverse events of these treatments. METHODS: Data from patients included in the ColHai registry treated with OCA, fibrates, or both were recorded during a year, as well as adverse events and treatment discontinuation. RESULTS: Eighty-six patients were treated with OCA, 250 with fibrates (81% bezafibrate; 19% fenofibrate), and 15 with OCA plus fibrates. OCA group had baseli…

Malemedicine.medical_specialtyPROGNOSISChenodeoxycholic AcidPLACEBO-CONTROLLED TRIALGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFenofibrateInternal medicinemedicineHumansBIOCHEMICAL RESPONSEAdverse effectCIRRHOSISRetrospective StudiesFenofibrateBezafibrateHepatologybusiness.industryLiver Cirrhosis BiliaryGastroenterologyObeticholic acidMiddle AgedBEZAFIBRATEUrsodeoxycholic acideye diseasesDiscontinuationURSODEOXYCHOLIC ACIDClinical trialTreatment Outcomechemistry030220 oncology & carcinogenesisAlkaline phosphatase030211 gastroenterology & hepatologyFemaleBezafibratebusinessmedicine.drug
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis : A longitudinal study of 1893 biopsy-proven no…

2021

[Background and Aim] Histological score systems may not fully capture the essential nonalcoholic steatohepatitis (NASH) features, which is one of the leading causes of screening failure in clinical trials. We assessed the NASH distribution and its components across the fibrosis stages and their impact on the prognosis and their relationship with the concept of metabolic-associated fatty liver disease (MAFLD).

Liver Cirrhosismedicine.medical_specialtyCirrhosisSteatosisBiopsyGastroenterologydigestive systemBallooning03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFatty liver diseaseInternal medicineBiopsyNonalcoholic fatty liver diseasemedicineassociated fatty liver diseaseMetabolic-associated fatty liver diseaseHumansmetabolic&#8208Longitudinal StudiesFirst episodeInflammationHepatologymedicine.diagnostic_testballooning fatty liver disease inflammation metabolic-associated fatty liver disease natural coursesteatohepatitis steatosisbusiness.industryFatty liverNatural coursesteatohepatitismedicine.diseasedigestive system diseasesLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologySteatosisSteatohepatitisbusiness
researchProduct

Análisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente

2014

Introducción: En España, con una prevalencia del 2,5%, la hepatitis C (VHC) se asocia a una elevada morbi-mortalidad. El tratamiento combinado de telaprevir y peginterferon/ribavirina ([T/PR]) es eficaz en pacientes con VHC-G1. El objetivo primario de este estudio fue evaluar la relación coste-utilidad (RCUI) de [T/PR] versus peginterferon alfa 2a/ribavirina ([PR]) en pacientes naïve VHC-G1, según el grado de fibrosis y bajo la perspectiva del sistema sanitario español. Metodología: La eficacia y la incidencia de efectos adversos (EAs) se obtuvieron de los estudios ADVANCE y OPTIMIZE. La estimación de los costes de monitorización, de manejo de EAs y de la enfermedad por estados de salud (€,…

; Genotype 1lcsh:RRibavirinalcsh:Medicinelcsh:RS1-441Genotype 1Hepatitis CTelaprevirGenotipo 1lcsh:Pharmacy and materia medicaCoste-utilidadCost-effectivenessPeginterferon alfa 2aRibavirinehealth care economics and organizationsFarmacia Hospitalaria
researchProduct

Advancing the global public health agenda for NAFLD: a consensus statement

2021

Digital

medicine.medical_specialtyCivil societyDelphi methodMEDLINENashMULTIDISCIPLINARY APPROACHDiseaseLATIN-AMERICAN ASSOCIATIONMultidisciplinary approachQUALITY-OF-LIFENon-alcoholic Fatty Liver DiseaseEpidemiologyMedicineHumansHumans; Non-alcoholic Fatty Liver DiseasePOSITION STATEMENTBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.FATTY LIVER-DISEASEBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Hepatologybusiness.industryPublic healthGastroenterologyALCOHOLIC STEATOHEPATITISNONINVASIVE DIAGNOSISmedicine.diseaseObesityCARDIOVASCULAR-DISEASEPRACTICE GUIDELINESFamily medicinePRACTICAL APPROACHHuman medicinebusiness
researchProduct

Análisis coste-utilidad de la triple terapia con telaprevir en pacientes con hepatitis C no tratados previamente

2014

Introducción: En España, con una prevalencia del 2,5%, la hepatitis C (VHC) se asocia a una elevada morbi-mortalidad. El tratamiento combinado de telaprevir y peginterferon/ribavirina ([T/PR]) es eficaz en pacientes con VHC-G1. El objetivo primario de este estudio fue evaluar la relación coste-utilidad (RCUI) de [T/PR] versus peginterferon alfa 2a/ribavirina ([PR]) en pacientes naïve VHC-G1, según el grado de fibrosis y bajo la perspectiva del sistema sanitario español. Metodología: La eficacia y la incidencia de efectos adversos (EAs) se obtuvieron de los estudios ADVANCE y OPTIMIZE. La estimación de los costes de monitorización, de manejo de EAs y de la enfermedad por estados de salud (€,…

Genotipo 1Coste-utilidadRibavirinaPeginterferon alfa 2aHepatitis CTelaprevir
researchProduct